BETA
Your AI-Trained Oncology Knowledge Connection!
AI Transforms HER2-Low, HER2-Ultralow Breast Cancer Diagnostics for Pathologists
AI-assisted training dramatically reduced HER2-null overscoring and improved sensitivity in HER2-low and HER2-ultralow breast cancer cases.
53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy
Frontline Lurbinectedin Plus Atezolizumab Enhances Survival in ES-SCLC
The phase 3 IMforte trial evaluating lurbinectedin plus atezolizumab is the first to show PFS and OS improvement with first-line maintenance for ES-SCLC.
Inavolisib Combo Significantly Extends Survival in PIK3CA+ Breast Cancer
Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.
GLP-1 Use Not Linked to Increased Obesity-Related Cancer Rates
There was a 7% lower incidence of obesity-related cancer with GLP-1 receptor agonist use.
Efficacy Data Support Nivolumab/Ipilimumab as First-Line HCC Treatment
Survival and safety data from the phase 3 CheckMate 9DW trial showed that nivolumab plus ipilimumab was superior to lenvatinib or sorafenib in advanced HCC.
China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL
Tafasitamab is the first CD19 antibody approved in China for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Trial Insights from TROPiCS-02 and DESTINY-Breast06 in HR+/HER2– Breast Cancer
Kit Yu Lu, MD, discussed the implications of the TROPiCS-02 and DESTINY-Breast06 trial data for sequencing ADCs in HR+/HER2– breast cancer.
The Radiation Oncology Perspective: Genomic vs Genetic Testing in Prostate Cancer
Decipher Prostate, Oncotype DX, and Prolaris are 3 gene expression testing options for patients with prostate cancers. Read as experts discuss them.
ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC
Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.
54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial
Exploring First-Line ALK Inhibitors, TKI Sequencing in ALK-Positive NSCLC
Given an unmet need for efficacious therapies against ALK-positive NSCLC, experts discuss optimal ALK TKI sequencing for patients with this disease.
Meeting With FDA “Successful” Regarding PT-112 in mCRPC
Following a positive meeting with the FDA, PT-112 is set to advance to a phase 3 trial for patients with metastatic castration-resistant prostate cancer.
FDA ODAC Votes 5-to-4 Against UGN-102 Intravesical Solution for Bladder Cancer
ODAC has voted against the use of UGN-102 intravesical solution for patients with advanced bladder cancer.
Comparing ADCs in HR+/HER2– Breast Cancer Without Head-to-Head Trials
Currently, sacituzumab govitecan, T-DXd, and Dato-DXd cannot be compared in HR+/HER2– breast cancer due to a lack of head-to-head trials.
Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer
"The data, even in fast progressors and within 6 months of endocrine therapy, [show it] is working," stated Monica Khunger Malhotra, MD.
2025 ASCO Annual Meeting: The Show and After Show
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?
ODAC Votes 6-2 For Benefit-Risk Profile of SQ Daratumumab in High-Risk Smoldering Multiple Myeloma
Based on the trial population and end point criteria, ODAC voted for daratumumab and hyaluronidase-fijh injection for SQ use in high-risk smoldering multiple myeloma.
Navigating Treatment/Testing Decisions in Metastatic HR+/HER2– Breast Cancer
Kit Yu Lu, MD, identifies patients with HR+/HER2– metastatic breast cancer who may benefit from earlier T-DXd or sacituzumab govitecan treatment.
FDA ODAC Votes 8-to-1 Against Applicability of Glofitamab DLBCL Data
The FDA’s ODAC convened to discuss the potentially inconsistent treatment effects of glofitamab between regional subgroups in the phase 3 STARGLO trial.
Perioperative Nivolumab Combo Earns EU Approval in PD-L1+ Resectable NSCLC
Findings from the CheckMate 77T study support the approval of this nivolumab-based regimen in the European Union.
ZL-1310 Receives FDA Fast Track Designation for Extensive-Stage SCLC
Creating an Accommodating Pediatric Cancer Care Experience
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
3 Things You Should Know About Advances in CLL Management
Care for patients with chronic lymphocytic leukemia continues to evolve via novel targeted therapies. Here are 3 things every cancer care specialist should know about treating CLL.
Belantamab Mafodotin Earns Japanese Approval in R/R Multiple Myeloma
Data from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin for patients with relapsed/refractory multiple myeloma in Japan.
56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?
Zanidatamab Displays Safety, Efficacy in HER2-Expressing Gastric Cancer
Antitumor activity was observed in patients with gastroesophageal adenocarcinoma treated with the combination regardless of chemotherapy type.
Cetuximab β/FOLFIRI Prolongs Survival vs FOLFIRI in RAS/BRAF Wild-Type mCRC
For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.
Phase 3 IDeate-Esophageal01 Trial Initiated for Unresectable ESCC
The trial initiation is based on phase 1/2 IDeate-PanTumor01 trial results presented at the 2022 and 2023 European Society for Medical Oncology Congress.
